Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term outcomes of recurrent IgA nephropathy treated with rituximab
TCTR20210427009Completed
- Sponsor
- N/A
- Start
- Apr 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of rituximab in IgA nephropathy (IgAN), sponsored by N/A. Started Apr 2021; status: completed.
02
Drugs
rituximab
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on TCTR20210427009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20210427009.